Braf
A gene whose mutations drive several cancers; a major target for precision drugs.
If Braf is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- WNT-driven immune evasion promotes malignant transformation of BRAF-mutant colorectal cancer. · Gastroenterology · 2026-08-18
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06
- Economic evaluation of newly approved cetuximab biosimilars for first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer in China. · Front Oncol · 2026-07-28
- Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry · Clinical Colorectal Cancer · 2026-07-26
- A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3 · Annals of Oncology · 2026-07-26
- Therapy-Induced Metastatic Melanoma During Treatment With Encorafenib and Cetuximab for BRAF-Mutated Colorectal Cancer: A Case Report and Short Literature Review · Clinical Colorectal Cancer · 2026-07-25
What the reporting says
It shows up alongside Colorectal Cancer (60), Egfr (17 — acquisition ×2), KRAS (17 — acquisition ×2), Immunotherapy (8).
Two steps out: AI (through Colorectal Cancer, 60 shared stories on the weaker link); ctDNA (through Colorectal Cancer, 60 shared stories on the weaker link); Wang (through Colorectal Cancer, 60 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 58 shared stories on the weaker link).
Tracked since Mar 15, with coverage on 63 separate days — concentrated in Oncology and Pubmed Targeted.